Synthetic approaches to Nδ-methylated L-arginine, N ω-hydroxy-L-arginine, L-citrulline, and Nδ- cyano-L-ornithine

Journal of Organic Chemistry

Volumn 73, Issue 3, 2008, Pages 1025-1030

  Schade, Dennis ^a   Töpker Lehmann, Katrin ^a   Kotthaus, Jürke ^a   Clement, Bernd ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE SYNTHASES; PHYSIOLOGICAL INHIBITORS;

BIOSYNTHESIS; DRUG PRODUCTS; ENZYME INHIBITION; NITRIC OXIDE; PHYSIOLOGY;

AMINO ACIDS;

9 BORABICYCLO[3.3.1]NONANE; ARGININE; BICYCLO COMPOUND; CITRULLINE; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; ORNITHINE; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CHEMICAL MODIFICATION; CHIRALITY; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SYNTHESIS;

ARGININE; BORON COMPOUNDS; CITRULLINE; MOLECULAR STRUCTURE; ORNITHINE; OXAZOLONE;

EID: 38849108141     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo702150d     Document Type: Article

References (43)

1. (a) Ignarro, L.; Murad, F., Eds. Nitric Oxide: Biochemistry, molecular biology, and therapeutic implications. In Advances in Pharmacology; Academic Press: San Diego, CA, 1995; Vol. 34.
2. (b) Alderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric oxide synthases: structures, function and inhibition. Biochem. J. 2001, 357, 593.
3. Vallance, P.; Leiper, J. Nat. Rev. Drug Discovery 2002, 1, 939.
4. Boucher, J. L.; Moali, C.; Tenu, J. P. Cell Mol. Life Sci. 1999, 55, 1015.
5. (a) Beltowski, J.; Kedra, A. Pharmacol. Rep. 2006, 58, 159.
6. (b) Cardounel, A. J.; Cui, H.; Samouilov, A.; Johnson, W.; Kearns, P.; Tsai, A. L.; Berka, V.; Zweier, J. L. J. Biol. Chem. 2007, 282, 879.
7. (a) Zobel-Thropp, P.; Gary, J. D.; Clarke, S. J. Biol. Chem. 1998, 273, 29283.
8. (b) Niewmierzycka, A.; Clarke, S. J. Biol. Chem. 1999, 274, 814.
9. Kotthaus, J.; Schade, D.; Töpker-Lehmann, K.; Beitz, E.; Clement, B. Bioorg. Med. Chem. 2007, doi: 10.1016/j.bmc.2007.11.066.
10. Stuehr, D. J.; Kwon, N. S.; Nathan, C. F.; Griffith, O. W.; Feldman, P. L.; Wiseman, J. J. Biol. Chem. 1991, 266, 6259.
11. (a) Clague, M. J.; Wishnok, J. S.; Marletta, M. A. Biochemistry 1997, 36, 14465.
12. (b) Rusche, K. M.; Spiering, M. M.; Marletta, M. A. Biochemistry 1998, 37, 15503.
13. Braun, V. J Ber. Dtsch. Chem. Ges. 1900, 33, 1438.
14. Hydroxylamine base was set free from its hydrochloride with sodium ethanolate. Steudel, R.; Schenk, P. W. In Handbuch der präparativen anorganischen Chemie, 3rd ed.; Brauer, G., Ed.; Ferdinand Enke Verlag: Stuttgart, Germany, 1975; Vol. 1, p 464.
15. (a) Zinner, G.; Kleinau, V. Chem.-Z. 1977, 10, 451.
16. (b) Belzecki, C.; Hintze, B.; Kwiatkowska, S. Bull. Acad. Pol. Sci. Chem. 1970, 18, 379.
17. ω-hydroxy-L-arginine: Clement, B.; Schnörwangen, E.; Kämpchen, T.; Mordvintcev, P.; Mülsch, A. Arch. Pharm. 1994, 327, 793.
18. 4, pH 1.5.
19. (a) Looper, R. E.; Runnegar, M. T.; Williams, R. M. Tetrahedron 2006, 62, 4549.
20. (b) Nordmann, R.; Loosli, H.-R. Helv. Chim. Acta 1985, 68, 1025.
21. Nefkens, G. H. L.; Zwanenburg, B. Tetrahedron 1983, 39, 2995.
22. (a) Diethylboryl complexation procedure under these conditions first described by Garcia et al. Tetrahedron: Asymmetry 2000, 11, 991.
23. (b) Luzzi, S. D.; Marletta, M. A. Bioorg. Med. Chem. Lett. 2005, 15, 3934.
24. (c) Described by Luzzi and Marletta for the diethylboryl complexes.
25. Rudinger, J.; Gut, V. Tetrahedron 1968, 24, 6351.
26. Erlanger, B. F.; Sachs, H.; Brand, E. J. Am. Chem. Soc. 1954, 76, 1806.
27. Yamamoto, H.; Yang, J. T. Biopolymers 1974, 13, 1093.
28. Benoiton, L. Can. J. Chem. 1964, 42, 2043.
29. Thomas, K.; Kapfhammer, J.; Flaschenträger, B. Hoppe-Seyler's Z. Physiol. Chem. 1923, 125, 75.
30. Klein, C.; Schulz, G.; Steglich, W. Liebigs Ann. Chem. 1983, 1623.
31. Paik, W. K.; Paik, K. P.; Sangduk, K. Anal. Biochem. 1980, 104, 343.
32. Protocols of different authors for synthetic intermediates leading to 10 and the final deprotecting step were considered and evaluated. Detailed synthetic protocols are provided in the Supporting Information along with the references. Note: So far reported characterization data were in most cases incomplete and are summarized in the Supporting Information.
33. (a) Dent, W. H., III; Erickson, W. R.; Fields, S. C.; Parker, M. H.; Tromiczak, E. G. Org. Lett. 2002, 4, 1249.
34. (b) Further articles reporting about similar application of 9-BBN-H: Cudic, M.; Mari, F.; Fields, G. B. J. Org. Chem. 2007, 72, 5581.
35. Syed, B. M.; Gustafsson T.; Kihlberg, J. Tetrahedron 2004, 60, 5571.
36. Walker, W. H., IV; Rokita, S. E. J. Org. Chem. 2003, 68, 1563.
37. A complete spectroscopic characterization of the herein described complexed intermediates is given in the Supporting Information, including 2D NMR experiments with 9-BBN complexes.
38. 9-BBN complex 12 was examined in terms of pH stability (HPTLC experiments, data not shown). It withstands even concentrated TFA over several hours, making it suitable in orthogonal sets, but hydrolyzes rapidly in dilute HCl as well as at pH > 6. Maximum stability was observed at pH 2-4.
39. Hydroxyguanidines are known to be most stable as salts of strong acids. Literature: (a) hydroxyguanidine: Walker, J. B.; Walker, M. S. J. Biol. Chem. 1959, 234, 1481.
40. ω-hydroxy-L-arginine: Fukuto, J. M. Meth. Enzymol. 1996, 268, 365.
41. Harris, J. I.; Work, T. S. Tetrahedron Lett. 2006, 47, 5159.
42. Feldman, P. L. Tetrahedron Lett. 1991, 32, 875.
43. Belyaev, A. A.; Krasko, E. V. Synthesis 1991, 5, 417.